期刊文献+

洛沙坦治疗糖尿病肾病的研究进展 被引量:2

暂未订购
导出
摘要 目的:介绍洛沙坦治疗糖尿病肾病的临床研究进展。方法:综合国内外文献资料特别是多中心、随机、双盲对照临床资料。结果:多项临床试验表明,每日口服洛沙坦50mg或100mg可显著降低2型糖尿病和蛋白尿患者肌酐血症加倍、终末期肾病(ESRD)或中枢性死亡的发生率。结论:洛沙坦有良好的耐受性,在糖尿病肾病治疗中有重要应用价值。
出处 《中国医院药学杂志》 CAS CSCD 北大核心 2005年第7期659-661,共3页 Chinese Journal of Hospital Pharmacy
  • 相关文献

参考文献21

  • 1刘景,修彬华,罗书练.洛沙坦临床应用中的不良反应[J].中国医院药学杂志,2000,20(2):126-127. 被引量:7
  • 2Timothy C, Evans, Peter C. American diabetes association[J].Diabetic Nephropathy, 1999,22(suppl. 1):66.
  • 3吴艺捷.糖尿病大血管病变的临床研究与治疗进展[J].现代实用医学,2003,15(7):405-407. 被引量:15
  • 4Mogensen CE. Renal risk and protection in patients with type 2 diabetes mellitus: new strategies for prevention and treatment[J].Treat in Endocrinol , 2002, 12:3.
  • 5Siragy H. Angiotensin Ⅱ receptor blockers: review of the binding characteristics[J]. Am J Cardiol, 1999,84(10A) :3S.
  • 6Simpson KL, McClellan KJ. Losartan:a review of its use, with special focus on elderly patients[J]. Drugs Aging , 2000, 16(3):227.
  • 7Tan KCB, Chow WS, Wong Y, et al. Effects of losartan on plasma C-reactive protein in type 2 diabetic patients with microalbuminuria [J]. Diabetes Care, 2002,25(7):1254.
  • 8Cheetham C, Collis J, ODriscoll G, et al. An angiotensin type 1receptor antagonist improves endothelial function non-insulin-dependent diabetes[J]. J Am Coll Cardiol, 2000,36(5) : 1461.
  • 9Cheetham C, O'Driscoll G, Stanton K, et al. Losartan , an angiotensin type 1 receptor antagonist, improves conduit vessel endothelial function in type 2 diabetes[J]. Clin Sci (Lond) , 2001,100(1):13.
  • 10Deininger E, Oltmanns KM, Wellhoener P, et al. Losartan attenuates symptomatic and hormonal responses to hypoglycemia in humans[J]. Clin Pharmacol Ther, 2001, 70(4):362.

二级参考文献27

  • 18,Birck R,Keim V,Fiedler F,et al.Pancreatitis after losartan[J].The Lanet,1998,351(9110):1178
  • 29,Bosch X.Losartan induced hepatotoxicity[J].JAMA,1997,278(19):1572
  • 310,Van Rijinsoever rea,Wilma J,Kwee zuiderwijk M.Angioneurotic edema attributed to the use of losartan[J].Arch Intern Med,1998,158(12):2063
  • 41,Goldberg AI,Dunlay MC,Sweet CS.Safety and tolerability of losartan potassium,a angiotensin Ⅱ receptro antagonist,compared with hydrochlorothiazide aienolol felodipine and angiotensin-converting enzyme inhibitors for the treatment of systemic hypertension[J].Am J Cardio,1995,75(12):793
  • 52,Gradman AH,Arcuike,Goldberg A,et al.A randomized,placebo controlled,double-blind, parallel study of various dose of losartan potassium compared with enalapril maleate in patients with essential hypertension[J].Hypertension,1995,(25):1345
  • 63,Schwarzbeck A,Wittenmeier KW,Hallfritzsch U.Anaemia in dialysis patients as a side-effect of sartanes[J].Lancet,1998,352(9124):286
  • 74,Horn S,Holzer H,Horina J.Losartan and renal transplantation[J].Lancet,1998,351(9096):111
  • 85,Heeringa M,Eugene P.Reversible dysgeusia attributed to losartan[J].Annals of Internal medicine,1998,129(1):72
  • 96,Bosch X.Henoch schonlein purpura induced by losartan therapy[J].ARCH Intern Med.1998,158(2):191
  • 107,Bosch X.Losartan induced acute pancreatitis[J].Annals of Internal Medicine,1997,127(11):1043

共引文献20

同被引文献11

引证文献2

二级引证文献13

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部